Evidence map›Paper›PMID 30139628›Full record

Trial reportEBioMedicine2018

Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs.

Mohamed Tharwat Hegazy, Walaa Ramadan Allam, Mohamed A Hussein, Naguib Zoheir, Luca Quartuccio, Sherif F El-Khamisy, Gaafar Ragab, Mediterranean Consortium for the study of Cryoglobulinemic Vasculitis

Abstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Leukemic conversion involvingFrontiers in oncology · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohamed Tharwat HegazyInternal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Giza, Egypt.
Walaa Ramadan AllamCenter for Genomics, Zewail City of Science and Technology, Giza, Egypt.
Mohamed A HusseinInternal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Giza, Egypt.
Naguib ZoheirClinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Luca QuartuccioClinic of Rheumatology, Department of Medical Area (DAME), University Hospital "Santa Maria della Misericordia", University of Udine, Udine, Italy.
Sherif F El-KhamisyCenter for Genomics, Zewail City of Science and Technology, Giza, Egypt; Krebs Institute, Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield, S10 2TN, UK. Electronic address: s.el-khamisy@sheffield.ac.uk.
Gaafar RagabInternal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Giza, Egypt. Electronic address: gragab@kasralainy.edu.eg.
Mediterranean Consortium for the study of Cryoglobulinemic Vasculitis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mixed Cryoglobulinemic Vasculitis (MCV) is a prominent extra-hepatic manifestation of Hepatitis C virus (HCV) infection. HCV has been reported to cause B-cell disorders and genomic instability. Here, we investigated B-cell activation and genome stability in HCV-MCV patients receiving the direct antiviral agent, Sofosbuvir, at multiple centers in Egypt. Clinical manifestations in HCV-MCV patients were improved at the end of treatment (EOT), such as purpura (100%), articular manifestations (75%) and neuropathy (68%). Eighteen patients (56%) showed vasculitis relapse after EOT. BAFF and APRIL were higher at EOT and continued to increase one year following treatment onset. Chromosomal breaks were elevated at EOT compared to baseline levels and were sustained at 3 and 6 months post treatment. We report increased expression of DNA genome stability transcripts such as topoisomerase 1 and TDP1 in HCV-MCV patients after treatment, which continued to increase at 12 months from treatment onset. This data suggest that B-cell activation and DNA damage are important determinants of HCV-MCV treatment outcomes.

Indexed as

Antiviral AgentsB-Cell Activating FactorB-LymphocytesCryoglobulinemiaCryoglobulinsDNA DamageFemaleGenomic InstabilityHepacivirusHumansMaleMiddle AgedRecurrenceSofosbuvirTumor Necrosis Factor Ligand Superfamily Member 13VasculitisAntiviral AgentsB-Cell Activating FactorCryoglobulinsSofosbuvirTNFSF13B protein, humanTumor Necrosis Factor Ligand Superfamily Member 13B cellCryoglobulinemic VasculitisDirect acting antiviralsDNA repairGenome instabilityHepatitis C VirusSofosbuvirTDP1TDP2Topoisomerase

Identifiers

PMID30139628
PMCPMC6156732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.